Rasagiline ( DrugBank: Rasagiline )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
5	進行性核上性麻痺	2
6	パーキンソン病	106
17	多系統萎縮症	10

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01786603 (ClinicalTrials.gov)	November 21, 2013	28/11/2012	Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis (ALS)	Drug: Rasagiline;Drug: Placebo	Richard Barohn, MD	NULL	Completed	21 Years	80 Years	All	80	Phase 2	United States
2	NCT01879241 (ClinicalTrials.gov)	June 2013	12/6/2013	Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients With Amyotrophic Lateral Scler ...	Amyotrophic Lateral Sclerosis	Drug: Rasagiline;Drug: Placebo	University of Ulm	NULL	Completed	18 Years	N/A	Both	252	Phase 2	Germany
3	EUCTR2011-004482-32-DE (EUCTR)	10/04/2013	21/12/2012	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients with Amyotrophic Lateral Scler ...	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients with Amyotrophic Lateral Scler ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term ...	Trade Name: AZILECT® 1 mg Tabletten INN or Proposed INN: RasagilineMesilate Other descriptive name: RA ...	Universitätsklinikum Ulm	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Germany
4	NCT01232738 (ClinicalTrials.gov)	December 2011	22/10/2010	Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagilinein Subjects With Amyot ...	Amyotrophic Lateral Sclerosis (ALS)	Drug: rasagiline	Yunxia Wang, MD	Western ALS Study Group	Completed	21 Years	80 Years	All	36	Phase 2	United States;Canada

First Previous1Next Last

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-007520-26-DE (EUCTR)	24/06/2010	13/11/2009	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerab ...	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerab ...	Progressive Supranuclear Palsy MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Pro ...	Trade Name: Azilect INN or Proposed INN: Rasagilin Other descriptive name: RASAGILINE MESILATE	Klinikum der Universität München	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Germany
2	NCT01187888 (ClinicalTrials.gov)	January 2010	20/8/2010	Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety ...	Progressive Supranuclear Palsy	Drug: Rasagiline;Drug: Sugar pill	Prof. Dr. Stefan Lorenzl	Teva Pharmaceutical Industries;Ludwig-Maximilians - University of Munich	Terminated	50 Years	80 Years	Both	44	Phase 3	Germany

First Previous1Next Last

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 10 of 106 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05611372 (ClinicalTrials.gov)	January 1, 2023	6/11/2022	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	REM Sleep Behavior Disorder;Parkinson Disease;Synucleinopathies	Drug: Rasagiline	Second Affiliated Hospital, School of Medicine, Zhejiang University	Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu P ...	Not yet recruiting	30 Years	75 Years	All	732	Phase 2/Phase 3	NULL
2	JPRN-JapicCTI-184181	01/11/2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's disease	Intervention name : Rasagiline INN of the intervention : rasagiline Dosage And administration of the i ...	TAKEDA PHARMACEUTICAL COMPANY LTD.	NULL	complete			BOTH	1021	NA	Japan
3	NCT03727139 (ClinicalTrials.gov)	November 1, 2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's Disease	Drug: Rasagiline	Takeda	NULL	Completed	N/A	N/A	All	1021		Japan
4	ChiCTR1800016949	2018-08-01	2018-07-04	Efficacy assessment and standard treatment of rasagilinein Chinese patients with early Parkinson's d ...	Efficacy assessment and standard treatment of rasagilinein Chinese patients with early Parkinson's d ...	Parkinson's disease	Rasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline;	Beijing Hospital	NULL	Pending	30	80	Both	Rasagiline early start group:130;Rasagiline delay start group:130;		China
5	EUCTR2017-001420-21-DE (EUCTR)	18/06/2018	16/02/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Paralle ...	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkins ...	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEX ...	Pharma Two B Ltd	NULL	Not Recruiting			Female: yes Male: yes	525	Phase 3	France;United States;Canada;Spain;Germany
6	EUCTR2017-001420-21-ES (EUCTR)	13/06/2018	15/03/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Paralle ...	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkins ...	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEX ...	Pharma Two B Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	525	Phase 3	United States;France;Canada;Spain;Germany
7	NCT03843944 (ClinicalTrials.gov)	May 1, 2018	12/2/2019	Overnight Switch From Rasagiline To Safinamide	Overnight Switch From RasagilineTo Safinamide In Fluctuating Patients With Parkinson's Disease: A To ...	Parkinson Disease	Drug: Safinamide	IRCCS San Raffaele Roma	NULL	Completed	30 Years	80 Years	All	20	Phase 4	Italy
8	NCT03329508 (ClinicalTrials.gov)	January 29, 2018	30/10/2017	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily ...	Parkinson Disease;Early Parkinson's Disease	Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER	Pharma Two B Ltd.	NULL	Active, not recruiting	35 Years	80 Years	All	525	Phase 3	United States;Canada;Germany;Spain
9	NCT02789020 (ClinicalTrials.gov)	December 2016	20/5/2016	Image Parkinson's Disease Progression Study	Image Parkinson's Disease Progression Study	Parkinson's Disease	Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Reson ...	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	40 Years	77 Years	All	96	Phase 2	United States
10	NCT02278588 (ClinicalTrials.gov)	November 2014	28/10/2014	Effect of 2.5 Years of RasagilineTherapy on Progression of Cognitive Biomarkers Assessed by MRI in P ...	Effect of 2.5 Years of RasagilineTherapy on Progression of Cognitive Biomarkers Assessed by MRI in P ...	Parkinson's Disease	Drug: Rasagiline	State University of New York at Buffalo	NULL	Completed	N/A	N/A	All	45		United States

First Previous1 2 3 4 5…11Next Last

先頭へ

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-014644-11-AT (EUCTR)	10/03/2010	21/10/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140		Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
2	EUCTR2009-014644-11-NL (EUCTR)	11/02/2010	29/10/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	243		Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
3	EUCTR2009-014644-11-PT (EUCTR)	05/02/2010	11/01/2010	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140		Hungary;Portugal;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
4	EUCTR2009-014644-11-GB (EUCTR)	25/01/2010	04/08/2010	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;Italy;United Kingdom
5	EUCTR2009-014644-11-IT (EUCTR)	10/12/2009	22/12/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian subtype (MSA-P) MedDRA version: 12.1;Level: LLT;Classifi ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140		Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria
6	EUCTR2009-014644-11-DE (EUCTR)	08/12/2009	15/09/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140		Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
7	NCT00977665 (ClinicalTrials.gov)	December 2009	15/9/2009	Clinical Trial to Assess Efficacy, Safety, and Tolerability of RasagilineMesylate 1 mg in Patients W ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy	Drug: rasagiline mesylate;Drug: placebo	Teva Pharmaceutical Industries	H. Lundbeck A/S	Completed	30 Years	N/A	All	174	Phase 2	United States;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United K ...
8	EUCTR2009-014644-11-FR (EUCTR)	17/11/2009	22/09/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
9	EUCTR2009-014644-11-ES (EUCTR)	22/10/2009	24/09/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) MedDRA version: 12.0;Level: P ...	Trade Name: AZILECT 1 mg comprimidos INN or Proposed INN: RASAGILINA MESILATO Other descriptive name: ...	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
10	EUCTR2009-014644-11-HU (EUCTR)	19/10/2009	25/09/2009	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy ...	Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification co ...	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	140		Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria

First Previous1Next Last

先頭へ